Chugai Initiates P-III Clinical Study of Actemra for COVID-19 Pneumonia in Japan

Chugai Initiates P-III Clinical Study of Actemra for COVID-19 Pneumonia in Japan

Shots:

  • Chugai has filed a clinical trial notification with the PMDA to conduct a P-III clinical study of Actemra (tocilizumab, IV, 80mg/200mg/400mg) to treat hospitalized patients with severe COVID19 pneumonia in Japan
  • The company will start enrolling once the details of the diseases get finalized. Earlier, Roche has initiated P-III COVACTA study assessing Actemra + SOC vs PBO + SOC in hospitalized patients with severe COVID-19 pneumonia across the globe including the US, Canada and EU
  • Actemra is a humanized anti-human IL-6 receptor mAb and has received the US FDA’s approval for RA in 2010 and was launched in Jun’2005 for multiple indications in Japan

Click here ­to­ read full press release/ article | Ref: Roche | Image: Chugai